ACAM2000天花疫苗在既往接种者中的四期安全性研究
本研究为开放标签、单臂、多中心四期研究,评估筛查算法筛选既往接种过天花疫苗的个体并再次接种ACAM2000疫苗的安全性。共筛查4088人,接种3032人,报告不良事件2478例,严重不良事件不常见(0.8%),未诊断心肌心包炎,疫苗耐受性良好。
要点
- 筛查算法可筛选出适合再次接种ACAM2000的既往接种者。
- 接种后严重不良事件发生率0.8%,仅2例与疫苗相关。
- 65例出现潜在心肌心包炎症状但均缓解,无确诊心肌心包炎。
核心结论
- ACAM2000疫苗在既往接种过天花疫苗的成年人群中耐受性良好。
研究设计与样本
- 开放标签、单臂、多中心四期研究,共筛查4088人,接种3032人。
- 受试者中位年龄51岁(范围18-65岁),75%为男性。
主要发现
- 3032名接种者中1420人(47%)报告2478例不良事件,其中1190人(39.2%)的1468例事件被认为与疫苗相关。
- 6人报告意外自体接种,但无需医疗干预。
- 65人出现潜在心肌心包炎症状但均缓解,无心肌心包炎诊断。
关键数值与推荐
- 最常见疫苗接种相关不良事件为皮肤反应和全身症状。
临床怎么用
- 对于既往接种过天花疫苗的高风险人群,可采用筛查算法评估后再次接种ACAM2000。
- 接种后需监测心肌心包炎相关症状,但本研究显示发生率低且症状可缓解。
局限性
- 本研究为单臂开放标签设计,无对照组。
- 研究人群为既往接种过天花疫苗的特定人群,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] is an attenuated vaccinia vaccine indicated in the US for active immunization for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection. The current study assessed the ability of a screening algorithm to identify a population of previously vaccinated individuals for whom revaccination with ACAM2000 vaccine could be used to assess safety (NCT02443623). Vaccination in this study stimulated anti-vaccinia antibodies in plasma donors for the preparation of vaccinia immune globulin intravenous (VIGIV). This was an open label, single-arm, multi-center study. The protocol criteria were designed to screen out individuals with risk factors associated with increased risk of adverse events, specifically myocarditis/pericarditis, including an algorithm to be followed in the event of symptom development. Post-vaccination safety data was collected including solicitation for symptoms of myocarditis/pericarditis. There were 4088 participants screened, of which 3032 were vaccinated, 850 failed the screening criteria and 206 were enrolled but not vaccinated. The median age was 51, ranged from 18 to 65, and was comprised of 75% males. Out of the 3032 vaccinated participants, 1420 (47%) reported 2478 adverse events (AEs), of which 1468 AEs in 1190 (39.2%) participants were considered related. Twenty-one participants (0.7%) reported severe events, serious adverse events were uncommon (0.8%), two were considered related to vaccination and there was one unrelated death. Inadvertent autoinoculation was reported in six participants but did not require medical intervention. The most frequently reported vaccination related AEs were cutaneous reactions and constitutional symptoms. Out of 3032 vaccinated participants, 65 had potential symptoms of myocarditis/pericarditis (myopericarditis) which were resolved, and there were no diagnoses of myopericarditis. Administration of ACAM2000 vaccine was well tolerated in this population of previously vaccinated participants.
引用
- Cassie D, Komlenovic V, Parrera G, et al. A phase 4, open-label, single arm, multi-center study to evaluate the safety of a smallpox vaccine in previously vaccinated individuals. Vaccine. 2026. PMID: 41621115. doi:10.1016/j.vaccine.2026.128289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。